Known targets — ChEMBL curated mechanism
AURKAAURKBAURKCBLKFGRFLT1FLT4FRKFYNHCKKDRLCKLYNPDGFRAPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Ilorasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 17/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 12/20 | 1.00 |
| ▸ | BLK known ✓ | P51451 | 10/20 | 1.00 |
| ▸ | AURKA known ✓ | O14965 | 10/20 | 1.00 |
| ▸ | FYN known ✓ | P06241 | 10/20 | 1.00 |
| ▸ | LYN known ✓ | P07948 | 9/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 9/20 | 1.00 |
| ▸ | LCK known ✓ | P06239 | 9/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 8/20 | 1.00 |
| ▸ | FRK known ✓ | P42685 | 7/20 | 1.00 |
| ▸ | SRMS known ✓ | Q9H3Y6 | 5/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 5/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 4/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 3/20 | 1.00 |
| ▸ | AURKC known ✓ | Q9UQB9 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 11/20 | 1.00 |
| ▸ | CSF1R | P07333 | 10/20 | 1.00 |
| ▸ | STK3 | Q13188 | 10/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 10/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilorasertib SCHEMBL29496449 | 1.00 | KDR (1.00) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL3381224 | 1.00 | KDR (1.00) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11898929 | 0.99 | KDR (0.98) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL30406133 | 0.99 | KDR (0.98) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11899788 | 0.97 | KDR (0.94) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11900182 | 0.97 | KDR (0.94) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11901361 | 0.97 | KDR (0.94) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL27917339 | 0.97 | KDR (0.94) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11899442 | 0.96 | KDR (0.93) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11899597 | 0.96 | KDR (0.91) | KDRAURKBFGFR1CSF1RBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2025245246-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250360130-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2025-11-27 | — | — | US | claimed |
| WO-2025244678-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | TELIOS PHARMA INC. (US) | 2025-09-16 | — | — | US | claimed |
| US-20250205375-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | ACTINIUM PHARMACEUTICALS, INC. | 2025-06-26 | — | — | US | claimed |
| WO-2025100428-A1 | COMBINATION OF ANTI-CD147 ANTIBODY AND ANOTHER ANTITUMOR AGENT | 第一三共株式会社 | 2025-05-15 | — | — | WO | claimed |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| US-11752150-B2 | Anti-tumor immunotherapy enhancer | NOBUO TSUKAMOTO (JP) | 2023-09-12 | — | — | US | claimed |
| US-20230248855-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | ACTINIUM PHARMACEUTICALS, INC. | 2023-08-10 | — | — | US | claimed |
| WO-2023129438-A1 | HYDROGEL COMPOSITIONS FOR USE FOR DEPLETION OF TUMOR ASSOCIATED MACROPHAGES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| CN-116334024-A | Aurora kinase B gene K85 and K87 mutation and application thereof | 北京大学 | 2023-06-27 | — | — | CN | claimed |
| WO-2023107477-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-06-15 | — | — | WO | claimed |
| US-20230174938-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2023-06-08 | — | — | US | claimed |
| CN-116004567-A | Aurora kinase B gene K202 mutation and application thereof | 北京大学 | 2023-04-25 | — | — | CN | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | DCX, SLC10A2, CHAT | KDR 4667/4885AURKB 3740/4885BLK 3462/4885 |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | BTK, LYN, ABL1 | KDR 3090/4885AURKB 282/4885BLK 9/4885 |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | WEE1, ERBB3, ERBB2 | KDR 72/4885AURKB 21/4885BLK 165/4885 |
| US-20250360130-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | BTK, LYN, ABL1 | KDR 3090/4885AURKB 282/4885BLK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.